PAM50-based ROR indexes as a tool to individualize the use of neoadjuvant endocrine therapy in ER+/HER2-breast cancer

被引：0
|
作者：
Lopez Velazco, J. I. [1 ]
Manzano, S. [1 ]
Elorriaga, K. [2 ]
Lahuerta Martinez, A. [3 ]
Alvarez, L. A. [4 ]
Etxabe Azkue, I. [4 ]
Huarte Martinez, M. [4 ]
Buch, E. [5 ]
Gimenez Climent, J. [6 ]
Quiroga Garcia, V. [7 ]
Aragon, S. [8 ]
Pare, L. [9 ]
Prat, A. [10 ]
Alvarez Lopez, I. [11 ,12 ]
Munoz Caffarel, M. [13 ,14 ]
Urruticoechea, A. [11 ,12 ]
机构：
[1] Biodonostia Hlth Res Inst, Dept Oncol, San Sebastian, Spain
[2] OSIDonostialdea Onkol, Pathol Unit, Gipuzkoa Pathol Unit, San Sebastian, Spain
[3] OSI Donostialdea Onkol, Dept Oncol, Gipuzkoa Canc Unit, San Sebastian, Spain
[4] General Surg Gynecol & Gen Surg Dept, Breast Unit, Onkol, San Sebastian, Spain
[5] Hosp Sagunto Hosp Clin Univ, Dept Oncol, Valencia, Spain
[6] Valencia Oncol Inst IVO, Dept Oncol, Valencia, Spain
[7] ICO Inst Catala Oncol Badalona Hosp Univ Germ, Dept Oncol, Badalona, Spain
[8] Hosp 12 Octubre, Dept Oncol, Madrid, Spain
[9] Hosp Clin Barcelona, Oncol Dept, Barcelona, Spain
[10] Hosp Clin Barcelona, Dept Med Oncol, Barcelona, Spain
[11] Biodonostia Hlth Res Inst, Dept Oncol, San Sebastian, Spain
[12] OSI Donostialdea Onkol, Gipuzkoa Canc Unit, San Sebastian, Spain
[13] Biodonostia Hlth Res Inst, Oncol Dept, Bilbao, Spain
[14] Ikerbasque, Basque Fdn Sci, Bilbao, Spain
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷
关键词：
D O I：
10.1016/j.annonc.2022.03.112
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
96P
引用
收藏
页码：S168 / S169
页数：2
相关论文
共 50 条
  • [21] Genomic characterization and oncology outcomes of a locally advanced ER+/HER2-breast cancer cohort treated with neoadjuvant chemotherapy
    Abreu, Maira
    Furlan, Larissa
    Ma, Yutong
    Chen, Hanlin
    Ferreira, Carla
    Fares, Aline
    Constantino, Eduardo
    Nora, Gustavo R.
    Lucio, Gabriela
    Colombo, Tatiana
    Liu, Rui
    Wu, Xue
    Ou, Qiuxiang
    Araujo, Daniel V.
    [J]. CANCER RESEARCH, 2023, 83 (05)
  • [22] Neoadjuvant (Z)-endoxifen in premenopausal ER+, HER2-breast cancer: Evaluation of the first pharmacokinetic cohort of the EVANGELINE trial
    Goetz, Matthew P.
    Suman, Vera J.
    Fraser, Heather
    Mina, Lida
    Advani, Pooja
    Leon-Ferre, Roberto
    Giridhar, Karthik
    Batalini, Felipe
    Hunt, Katie N.
    Jayaraman, Swaathi
    Jakub, James
    Cronin, Patricia
    Piltin, Mara
    Degnim, Amy
    Ingle, James N.
    Boughey, Judy C.
    Buhrow, Sarah
    Reid, Joel
    Schellenberg, Matthew
    Hawse, John
    Quay, Steven
    [J]. CANCER RESEARCH, 2024, 84 (07)
  • [23] Independent validation of the PAM50-based chemo-endocrine score (CES) in hormonal receptor positive (HR+)/HER2+breast cancer (BC) treated with neoadjuvant (NA) anti-HER2-based therapy
    Pascual, Tomas
    Tanioka, Maki
    Dieci, M. Vittoria
    Pernas, Sonia
    Gavila, Joaquin
    Guarnieri, Valentina
    Cortes, Javier
    Llombart, Antonio
    Conte, Pierfranco
    Oliveira, Mafalda
    Pare, Laia
    Galvan, Patrica
    Perou, Charles M.
    Prat, Aleix
    Carey, Lisa
    [J]. CANCER RESEARCH, 2018, 78 (04)
  • [24] Unraveling Vulnerabilities in Endocrine Therapy-Resistant HER2+/ER+ Breast Cancer
    Bahnassy, Shaymaa
    Stires, Hillary
    Jin, Lu
    Tam, Stanley
    Mobin, Dua
    Balachandran, Manasi
    Podar, Mircea
    Mccoy, Matthew D.
    Beckman, Robert A.
    Riggins, Rebecca B.
    [J]. ENDOCRINOLOGY, 2023, 164 (12) : 1 - 15
  • [25] Phase II study of adjuvant endocrine therapy with CDK 4/6 inhibitor, ribociclib, for localized ER+/HER2-breast cancer (LEADER).
    Spring, Laura
    Griffin, Colleen
    Isakoff, Steven J.
    Moy, Beverly
    Wander, Seth Andrew
    Shin, Jennifer
    Abraham, Elizabeth
    Habin, Karleen
    Patel, Jaymin M.
    Comander, Amy H.
    Mulvey, Therese Marie
    Bardia, Aditya
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [26] Axillary Downstaging in ER+/HER2- Breast Cancer: OncotypeDX As a Tool to Guide Neoadjuvant Approach
    Kantor, Olga
    Coopey, Suzanne B.
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2021, 28 (03) : 1265 - 1267
  • [27] Axillary Downstaging in ER+/HER2− Breast Cancer: OncotypeDX As a Tool to Guide Neoadjuvant Approach
    Olga Kantor
    Suzanne B. Coopey
    [J]. Annals of Surgical Oncology, 2021, 28 : 1265 - 1267
  • [28] Replication of risk characterization in a cohort with women with advanced ER+/HER2-breast cancer using a new analytic tool
    Zhou, Xiaofeng
    de Luise, Cynthia
    Prince, Patricia
    Shen, Rongjun
    Luo, Kaiyi
    Louder, Anthony
    Gatto, Nicolle M.
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2019, 28 : 66 - 67
  • [29] Nivolumab with neoadjuvant chemotherapy and adjuvant endocrine therapy in ER+/HER2-primary breast cancer: CheckMate 7FL
    Loi, Sherene
    McArthur, Heather
    Harbeck, Nadia
    Pusztai, Lajos
    Delaloge, Suzette
    Letrent, Kristen
    Chen, Tian
    Li, Bin
    Tatsuoka, Kay
    Zardavas, Dimitrios
    Curigliano, Giuseppe
    [J]. CANCER RESEARCH, 2020, 80 (04)
  • [30] Genomic Testing on Core Needle Biopsy Samples from Newly Diagnosed ER+/HER2-Breast Cancer Patients Decreases Use of Neoadjuvant Chemotherapy
    Anzar, Amna
    Knight, Joy
    Bomeisl, Philip
    Montero, Alberto
    Gilmore, Hannah
    [J]. LABORATORY INVESTIGATION, 2023, 103 (03) : S92 - S92
12345